A comprehensive review study has found that Medicaid and commercial insurance coverage policies for Biogen Alzheimer’s disease drug, Aduhelm, showed large inconsistencies based on plan and geography.
Once barely able to walk and given less than six months to live, Linda DaCosta is alive and thriving years later, thanks to her care at Tufts Medical Center.